Jazz Pharmaceuticals plc (JAZZ) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 1.02B USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 3.33B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Available-for-sale Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 11.08B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $1.02B | $3.33B | (m) | (m) | $11.08B | (m) |
| 2026-03-31 | (m) | (m) | $1.03B | $4.32B | (m) | (m) | $11.86B | (m) |
| 2025-12-31 | (m) | (m) | $1.03B | $4.33B | (m) | (m) | $11.66B | (m) |
| 2025-09-30 | (m) | (m) | $1.03B | $4.33B | (m) | (m) | $11.36B | (m) |
| 2025-06-30 | (m) | (m) | $1.03B | $4.34B | (m) | (m) | $10.94B | (m) |
| 2025-03-31 | (m) | (m) | $31.00M | $5.34B | (m) | (m) | $11.53B | (m) |
| 2024-12-31 | (m) | (m) | $31.00M | $6.08B | (m) | (m) | $12.01B | (m) |
| 2024-09-30 | (m) | (m) | $31.00M | $6.08B | (m) | (m) | $12.26B | (m) |
| 2024-06-30 | (m) | (m) | $605.80M | $5.10B | (m) | (m) | $11.36B | (m) |
| 2024-03-31 | (m) | (m) | $605.38M | $5.11B | (m) | (m) | $11.33B | (m) |
| 2023-12-31 | (m) | (m) | $604.95M | $5.11B | (m) | (m) | $11.39B | (m) |
| 2023-09-30 | (m) | (m) | $604.51M | $5.11B | (m) | (m) | $11.20B | (m) |
| 2023-06-30 | (m) | (m) | $31.00M | $5.69B | (m) | (m) | $11.26B | (m) |
| 2023-03-31 | (m) | (m) | $31.00M | $5.69B | (m) | (m) | $11.05B | (m) |
| 2022-12-31 | (m) | (m) | $31.00M | $5.69B | (m) | (m) | $10.84B | (m) |
| 2022-09-30 | (m) | (m) | $31.00M | $5.70B | (m) | (m) | $10.38B | (m) |
| 2022-06-30 | (m) | (m) | $31.00M | $5.99B | (m) | (m) | $11.20B | (m) |
| 2022-03-31 | (m) | (m) | $31.00M | $5.99B | (m) | (m) | $11.77B | (m) |
| 2021-12-31 | (m) | (m) | $31.00M | $6.02B | (m) | (m) | $12.30B | (m) |
| 2021-09-30 | (m) | (m) | $31.00M | $6.25B | (m) | (m) | $12.48B | (m) |
| 2021-06-30 | (m) | (m) | $248.59M | $6.49B | (m) | (m) | $13.21B | (m) |
| 2021-03-31 | (m) | (m) | $248.61M | $1.85B | (m) | (m) | $6.76B | (m) |
| 2020-12-31 | (m) | (m) | $246.32M | $1.85B | (m) | (m) | $6.54B | (m) |
| 2020-09-30 | (m) | (m) | $244.00M | $1.84B | (m) | (m) | $6.29B | (m) |
| 2020-06-30 | (m) | (m) | $33.39M | $2.07B | (m) | (m) | $6.07B | (m) |
| 2020-03-31 | (m) | (m) | $33.39M | $1.58B | (m) | (m) | $5.22B | (m) |
| 2019-12-31 | (m) | (m) | $33.39M | $1.57B | (m) | (m) | $5.54B | (m) |
| 2019-09-30 | (m) | (m) | $33.39M | $1.57B | (m) | (m) | $5.53B | (m) |
| 2019-06-30 | (m) | (m) | $33.39M | $1.57B | (m) | (m) | $5.49B | (m) |
| 2019-03-31 | (m) | (m) | $33.39M | $1.57B | (m) | (m) | $5.28B | (m) |
| 2018-12-31 | (m) | (m) | $33.39M | $1.56B | (m) | (m) | $5.20B | (m) |
| 2018-09-30 | (m) | (m) | $33.39M | $1.56B | (m) | (m) | $5.49B | (m) |
| 2018-06-30 | (m) | (m) | $33.39M | $1.56B | (m) | (m) | $5.35B | (m) |
| 2018-03-31 | (m) | (m) | $45.12M | $1.54B | (m) | (m) | $5.29B | (m) |
| 2017-12-31 | (m) | (m) | $40.60M | $1.54B | (m) | (m) | $5.12B | (m) |
| 2017-09-30 | (m) | (m) | $36.09M | $1.54B | (m) | (m) | $5.00B | (m) |
| 2017-06-30 | (m) | (m) | $36.09M | $1.64B | (m) | (m) | $4.80B | (m) |
| 2017-03-31 | (m) | (m) | $136.09M | $1.74B | (m) | (m) | $4.82B | (m) |
| 2016-12-31 | (m) | (m) | $36.09M | $1.99B | (m) | (m) | $4.80B | (m) |
| 2016-09-30 | (m) | (m) | $36.09M | $2.15B | (m) | (m) | $4.93B | (m) |
| 2016-06-30 | (m) | (m) | $37.50M | $1.14B | (m) | (m) | $3.45B | (m) |
| 2016-03-31 | (m) | (m) | $37.59M | $1.15B | (m) | (m) | $3.53B | (m) |
| 2015-12-31 | (m) | (m) | $37.59M | $1.17B | (m) | (m) | $3.36B | (m) |
| 2015-09-30 | (m) | (m) | $117.59M | $1.17B | (m) | (m) | $3.46B | (m) |
| 2015-06-30 | (m) | (m) | $28.48M | $1.34B | (m) | (m) | $3.39B | (m) |
| 2015-03-31 | (m) | (m) | $9.39M | $1.33B | (m) | (m) | $3.24B | (m) |
| 2014-12-31 | (m) | (m) | $9.43M | $1.33B | (m) | (m) | $3.34B | (m) |
| 2014-09-30 | (m) | (m) | $9.44M | $1.33B | (m) | (m) | $3.35B | (m) |
| 2014-06-30 | (m) | (m) | $9.47M | $1.19B | (m) | (m) | $3.16B | (m) |
| 2014-03-31 | (m) | (m) | $9.51M | $1.19B | (m) | (m) | $3.20B | (m) |
| 2013-12-31 | (m) | (m) | $5.57M | $544.40M | (m) | (m) | $2.24B | (m) |
| 2013-09-30 | (m) | (m) | $5.57M | $545.56M | (m) | (m) | $2.19B | (m) |
| 2013-06-30 | (m) | (m) | $5.57M | $546.72M | (m) | (m) | $2.09B | (m) |
| 2013-03-31 | (m) | (m) | $32.66M | $418.51M | (m) | (m) | $2.01B | (m) |
| 2012-12-31 | (m) | (m) | $29.69M | $427.07M | (m) | $387.20M | $1.97B | (m) |
| 2012-09-30 | (m) | (m) | $26.72M | $435.63M | (m) | $189.79M | $1.73B | (m) |
| 2012-06-30 | (m) | (m) | $23.75M | $444.19M | (m) | (m) | $1.70B | (m) |
| 2011-12-31 | (m) | (m) | $0.00 | $0.00 | (m) | $157.90M | $253.57M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |